
News From New Mexico: A Cauldron Of Energy Uncertainty
35% of New Mexico's revenue comes from oil and gas fields in the Delaware basin, part of the Permian basin that stretches into West Texas. Crude production exceeded 2 MMbopd (million barrels per day) in 2024, which was double that in 2019 before the Covid dropout in 2020. The entire Permian basin reached 6 MMbopd in 2024, about half of total U.S. crude production.
But what will happen if the price of oil stays low? If the WTI price of oil stays at $63/barrel, Permian drilling of well inventory will last seven - ten years. This is better than three - four years for the Eagle Ford in East Texas, and the Bakken in North Dakota. But it illustrates one potential downside if the price of oil stays low.
Another downside is a projection by Vicki Hollub, CEO of Occidental, who said crude production in the Permian could peak by next year, due to cutbacks in capital spending.
Oil and gas production is one ingredient in the cauldron of uncertainties because 35% of New Mexico's revenue comes from the Delaware basin. Another ingredient is that oil and gas globally produces about 50% of greenhouse gases (GHG) that cause global warming. The oil and gas industry is responsible for the largest fraction of emissions in New Mexico at 41%.
Although there is a growing industry of renewable energies in New Mexico, and lots of government support, the revenue from this will never replace the revenue from oil and gas.
Another dilemma faced by New Mexico is the enormous volume of water that flows to the surface along with oil and gas—so called produced water. 2 billion barrels or 84 billion gallons are produced each year. Right now, this water is left in evaporation ponds, or disposed of in injected wells, or recycled and cleaned to be used in the next frac job. Disposal by deep injection is problematic because it has created earthquakes of magnitude 5, although this has been more of an issue in West Texas.
The dilemma is exacerbated because the Permian basin is largely a desert, and New Mexico is in a drought—some say a 20-year drought. A solution that cries out loud is to purify the produced water enough that it can be used in agriculture, or perhaps even drinking water. There are a range of systems from multi-stage filtration up to commercial desalination that can be used, but to achieve the required purification would be costly.
Twelve pilot projects are underway to test the effects of treated water on agriculture and manufacturing. But the New Mexico Water Quality Control Commission stepped in last month to prohibit the next step—discharge of treated water to ground or streams. The Commission fears that chemicals still in treated produced water will be toxic, but there are no regulations governing their use.
As well as water treatment, the state would need to oversee storage, transport, and disposal of the water. Although there are no regulations for this, NMED (New Mexico Environmental Department) plans to use results from the pilot projects to design new standards, technical and operational, that would allow re-use of produced water to help resolve the fresh water problem in New Mexico.
Chaco Canyon was a central gathering place of Indian tribes around 1100 A.D. Eight man-made roads extended radially outwards, some for 50 miles or so. The large collection of ruins at Chaco include separate multi-story buildings and many circular kivas, underground religious centers. Carvings in sheltered sandstone clefts and alignment of structural walls reveal native knowledge of yearly seasons of the sun and moon.
Chaco Canyon lies in the San Juan basin, once the largest gas basin in the U.S. Chaco has been simmering in the New Mexico cauldron for a number of years. In 2023, Secretary of the Interior, Deb Haaland issued an order to restrict drilling or development of oil and gas operations to outside a 10-mile radius around Chaco. This was to enlarge the area of protection around Chaco Canyon, which is sacred to many Indian tribes. But not all tribes, as the Navajo Tribe did not live in the region until hundreds of years after 1100 A.D.
The details of this issue have been spelled out separately. Chaco sits close to the southern edge of the oily window of the San Juan basin. In 2023, the Navajo Nation had wanted to specify a smaller radius of 5 miles, because some members owned mineral rights to some of the land around Chaco. They filed a lawsuit against the Interior Department and BLM (Bureau of Land Management) in January of 2025, arguing to revoke the 10-mile limit because it harmed the profits of lessees who were economically small operators.
Into the breach has stepped the Trump administration. New Interior Secretary, Doug Burgum, has told the BLM to reconsider the 10-mile limit. The All Pueblo Council of Governors has resisted this, but not the Navajo Nation. Given the Trump government's directive to revise or rescind actions that are an 'undue burden on the development of domestic energy resources', it's hard to see the BLM keeping the 10-mile protective limit at Chaco.
New Mexico was a hotspot of uranium mining back in the 1950s and 1960s when the cold war was at its height. Over 1,000 uranium mines came into existence, many that employed miners from the Navajo Nation. The uranium was bought by the U.S. government to be used for nuclear defense purposes. Church Rock just outside Gallup was an active mining site, and the scene of a bad flood that polluted the Rio Puerco in 1979—the largest-ever radiation accident in the U.S.
The health effects of mining, notably lung disease due to radon gas attached to mining dust, is a dark chapter in the history of mining. Lack of epidemiological studies and government bureaucracy delayed cleanup efforts for surface tailings radiation, and underground contamination of aquifers.
The U.S. Congress eventually passed RECA, an act that provided reparations to people affected by uranium mining and by nuclear tests in Nevada. The law was due to expire in June 2024, but the Senate passed a bill to extend it by six years. However, the House never brought it to a vote, so the law has expired. Under RECA, the government has paid claims of 41,000 people, and paid $2.6 billion in reparations, the majority to recipients from the Nevada nuclear testing site.
The Inflation Reduction Act of 2022 opened a door to nuclear power as an alternative energy source, to the tune of $30 billion. This would include reopening of old mines, many of which lie on Native land, as well as new mines.
The Trump government appears to have taken another giant step toward uranium mining by another new executive order on May 23 that prioritized nuclear fission reactors, traditional and SMRs (small modular reactors). This was ostensibly to provide burgeoning new electricity needed for U.S. data centers. According to the Secretary of Energy, 'Nuclear has the potential to be America's greatest source of energy addition. It works whether the wind is blowing, or the sun is shining, is possible anywhere and at different scales.'
Given the state's history, a lot of tension will arise if uranium mining is allowed to resume in New Mexico. Untrammeled growth of uranium mining and nuclear generation of electricity may ignite a spark to the ever-present fear of radioactivity in mining and disposal of nuclear waste, which are always simmering in the New Mexico cauldron of uncertainty.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Why Google should 'walk away' from Waymo
Needham & Company senior media and internet analyst Laura Martin joins Market Domination with Josh Lipton to explain why Alphabet (GOOG, GOOGL) should ditch Waymo and focus on generative artificial intelligence (AI) instead. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Related videos The £70bn pension tax raid Reeves may not be able to resist 10 shares I wouldn't want to hold in a stock market crash After falling 16% in a day, this stock's on my list of shares to buy in August This FTSE 250 trust is easily beating the global index in 2025. Time to buy? Sign in to access your portfolio
Yahoo
7 minutes ago
- Yahoo
EMCOR Group (EME) Sees EPS Surge as Net Income Climbs to US$241 Million
EMCOR Group recently announced a regular quarterly cash dividend of $0.25 per common share, to be paid on July 31, 2025. This steady dividend approach aligns with the company's robust quarterly performance, which saw net income rise to $241 million and EPS increase substantially year-over-year. Additionally, the ongoing share buyback program has strengthened shareholder returns. Despite the broader market's moderate growth of 1.4% over the past week and 17% over the past year, EMCOR's notable share repurchases and solid financial outcomes appear to have amplified investor confidence, contributing to the company's impressive 55% stock price surge last quarter. We've spotted 1 risk for EMCOR Group you should be aware of. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. EMCOR Group's recent announcement of a quarterly dividend and the implementation of its share buyback program underline its commitment to enhancing shareholder returns. Despite a potential downside to the current share price of US$635.06, which exceeds the consensus analyst price target of US$549.57 by 13.46%, these actions could continue to buoy investor confidence. The company's performance over the past five years, with a total return exceeding 844.60%, showcases its robust long-term trajectory. In the last year, EMCOR's share performance exceeded both the broader market's 17.2% and the US Construction industry's 54.2% return, highlighting its strong standing relative to peers. The successful integration of acquisitions and strategic diversification into sectors like data centers and healthcare is anticipated to impact future revenue positively. This, coupled with operational efficiencies and strong revenue collaboration, may reinforce earnings projections. However, EMCOR's earnings forecasts of a 6.2% annual growth rate lag behind the broader market's 14.9% forecast, which could present challenges in meeting broader industry expectations. The company's impressive share price rise of 55% last quarter signals optimism, though its current value being above the target may indicate overvaluation concerns. Nevertheless, the consistent cash flow and healthy margins underscore its potential resilience against margin pressures, supply chain challenges, and other economic uncertainties. As analysts estimate revenue growth to 7.9% annually over the next three years, any tangible improvement in operational metrics could shift the valuation outlook positively. Unlock comprehensive insights into our analysis of EMCOR Group stock in this financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include EME. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 minutes ago
- Yahoo
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY
BioNTech SE and Pfizer recently received a positive recommendation from the European Medicines Agency for marketing authorization of their COVID-19 vaccine, which likely contributed to Pfizer's share price increase of 8% in the last quarter. The company's advancements in COVID-19 vaccine development, alongside other product-related announcements like the XTANDI and BRAFTOVI trial results, added weight to this upward movement. Despite legal challenges and declining earnings, Pfizer's focus on innovation and strategic partnerships like the one with XtalPi possibly countered broader market moves, which saw a smaller 1% increase in the same period. We've identified 3 warning signs for Pfizer that you should be aware of. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent positive recommendation from the European Medicines Agency for the COVID-19 vaccine developed by BioNTech SE and Pfizer has contributed to an 8% increase in Pfizer's share price over the last quarter. This news may provide a temporary boost to Pfizer's revenue and earnings forecasts, especially as the company continues to innovate amidst legal challenges and declining earnings. The authorization could enhance immediate market confidence in Pfizer's product pipeline, impacting future revenue projections positively. Over the past year, Pfizer experienced a total return of 13.78% including dividends, reflecting a challenging period for shareholders. When compared to the broader US market's return of 17.2% over the same period, Pfizer has underperformed, highlighting investor concerns over competitive pressures and revenue growth prospects. The current share price movement toward the analyst consensus price target of $29.23 suggests a cautiously optimistic outlook among some market participants. Analysts' revenue forecasts reflect potential declines due to increased competition for existing products, yet others anticipate that strategic shifts in research focus, especially in oncology, might mitigate future earnings risks. With a modest increase of 8% in shares largely tied to vaccine authorization, it underscores the uncertainty surrounding longer-term performance relative to bearish analyst expectations. Understand Pfizer's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@